New J&J BabyCenter app feeds advice to parents of kids 1-8
SAN FRANCISCO – BabyCenter, a Johnson & Johnson company, on Thursday launched its new app Mom Feed for iPhone and iPad. Mom Feed provides bite-size ideas to time-starved parents, giving them expert advice for parents with children ages 1 through 8.
According to BabyCenter’s State of Modern Motherhood Report, digital resources are essential for moms beyond their child’s first year. In fact, nearly 30% of moms with children ages 1 and up say they use parenting/baby apps weekly or more often, and expert advice from parenting websites remains Mom’s No. 1 source for parenting-related information.
“We’re thrilled to be offering a new app that’s specifically designed to meet the needs of moms with children over age 1,” said Linda Murray, BabyCenter Global editor in chief. “We know moms are hungry for bite-size nuggets of information streamed to them throughout the day. Our Mom Feed app blends nuts-and-bolts parenting advice on topics like sleep, potty training and behavior, with hilarious mom stories and you’re-not-alone advice from other parents. Mom Feed is the best of BabyCenter in a convenient new package for our fans who’ve graduated from the pregnancy and baby stage.”
Mom Feed expands BabyCenter’s portfolio of successful apps, including My Pregnancy Today and My Baby Today, which have been enjoyed by new and expecting parents, and reinforces the company’s dedication to being there for Mom at every stage of her maternal journey.
Mom Feed will also be available for Android beginning October 1, 2015.
Hi-Tech continues to beef up sports nutrition portfolio
NORCROSS, Ga. – Hi-Tech Pharmaceuticals continues to beef up its sports nutrition product portfolio with the acquistion of Sports One brands Amphedrine, Andro-XS, Better Whey, and Solid Mass. The acquisition comes days after the company's purchase of Innovative's sports nutrition portfolio.
"Sports One products will serve as a growth catalyst for our sports supplement segment, providing this division with another leading brand in the high-growth sports nutrition category," said Steve Smith, EVP Hi-Tech Pharmaceuticals.
Hi-Tech's recent strategy has been, and according to its leaders will continue to be, growth through M&A activity. Hi-Tech has been able to increase its market share in the United States through the acquisition of Florida-based Synergy Nutritional Industries in 2005, and gained a larger market share when it acquired Advanced Performance Supplements in 2011. Hi-Tech gained further marketshare when it acquired Nittany Pharmaceuticals in Pennsylvania and ALR Industries in California in 2012. In 2015, Hi-Tech has acquired Advanced Pharmaceuticals and Nutritionals, FormuTech Nutrition, Innovative Laboratories and with the most recent acquisition by Hi-Tech of Sports One it is the fourth acquisition for Hi-Tech and will not be the last of the year, the company stated.
Aspirin may prevent progression of mesothelioma, research finds
HONOLULU — Aspirin may inhibit the growth of mesothelioma, an aggressive asbestos-related cancer, University of Hawai'i Cancer Center researchers reported Monday.
The study published in Cell Death and Disease showed that aspirin slows down the growth of mesothelioma by blocking the carcinogenic effects of the inflammatory molecule, High-Mobility Group Box 1 (HMGB1). Researchers believe the molecule directly promotes mesothelioma growth.
"HMGB1 is an inflammatory molecule that plays a critical role in the initiation and progression of malignant mesothelioma," stated Haining Yang, associate professor in the Thoracic Oncology Program at the UH Cancer Center. "Inhibiting HMGB1 dramatically reduced malignant mesothelioma growth in mice and significantly improved survival of treated animals."
Aspirin is mostly used as a nonsteroidal anti-inflammatory drug, which is absorbed by the stomach and upper intestine. Working with collaborators, Yang and Michele Carbone, director of the UH Cancer Center's Thoracic Oncology Program, found that at least some of the so far unknown anti-tumor activity of aspirin is through preventing HMBG1 activity.
Malignant mesothelioma is an aggressive and often deadly cancer that can result from exposure to asbestos and asbestos-like fibers such as erionite. The prolonged presence of asbestos fibers lodged in the organ lining initiates a vicious cycle of chronic cell death and chronic inflammation that, over a period of many years, can lead to mesothelioma.
The researchers theorized that people at high risk of developing mesothelioma could take aspirin as a way to prevent or delay the growth of the cancer, and thus increase their chances of survival. Such individuals would include people occupationally exposed to asbestos, or people who live in areas high in naturally occurring asbestos-like fibers. They also encourage future studies to uncover the precise mechanism by which aspirin blocks HMGB1.
Loading Post Please Wait...